Schisantherin B

Synonyms: 五味子酯乙; Gomisin-B; Wuweizi ester-B; Schisantherin-B
Schisantherin B(Gomisin-B)是一种木脂素类化合物,是五味子的活性成分之一,可激活 PI3K/AKT 信号通路、恢复 GSK3β 活性、减少海马体和大脑皮层组织中的 tau 蛋白过度磷酸化、上调 GLT-1 水平、降低促炎细胞因子 TNF-α/IL-1β/IL-6 的表达、上调 IL-10 的表达并抑制细胞凋亡 (apoptosis),可用于脊髓损伤、阿尔茨海默病和抑郁症研究。
产品编号: MS-O75025 纯度: 99.75% CAS No.: 58546-55-7 分子式: C28H34O9 分子量: 514.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Schisantherin B(Gomisin-B)是一种木脂素类化合物,是五味子的活性成分之一,可激活 PI3K/AKT 信号通路、恢复 GSK3β 活性、减少海马体和大脑皮层组织中的 tau 蛋白过度磷酸化、上调 GLT-1 水平、降低促炎细胞因子 TNF-α/IL-1β/IL-6 的表达、上调 IL-10 的表达并抑制细胞凋亡 (apoptosis),可用于脊髓损伤、阿尔茨海默病和抑郁症研究。

生物实验数据

生物活性 Schisantherin B (Gomisin-B) is a lignan compound and one of the active constituents of Schisandra chinensis that activates the PI3K/AKT signaling pathway, restores GSK3β activity, reduces tau hyperphosphorylation in hippocampal and cerebral cortical tissues, upregulates GLT-1 levels, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates IL-10 expression, and inhibits apoptosis, and can be used for research on spinal cord injury, Alzheimer's disease, and depression.
体外研究
(In Vitro)

Schisantherin B (25 μM; 4 h) 可提高 H2O2 处理的 PC12 细胞的存活率、抑制细胞凋亡并激活 PI3K/AKT 通路。

Cell Viability Assay

Cell Line: PC12 cells
Concentration: 25 μM (co-incubated with 90 μM H2O2)
Incubation Time: 4 hours
Result: Increased PC12 cell viability to 66.15% (compared to 40.86% in the H2O2-only group).
Reduced the apoptotic cell percentage to 5.84% (compared to 10.81% in the H2O2-only group).
Significantly decreased mean fluorescence intensity (MFI) of cleaved caspase-3.
Significantly upregulated MFI of phosphorylated PI3K (p-PI3K) and phosphorylated AKT (p-AKT) compared to the H2O2-only group.
体内研究
(In Vivo)

Schisantherin B (15 mg/kg;腹腔注射;每日 1 次;连续 10 天) 可在强迫游泳试验 (FST) 诱导抑郁的小鼠中发挥类抗抑郁作用,改善 FST 诱导的短期记忆损伤,并恢复海马 GLT-1 及 PI3K/AKT/mTOR 通路的活性。
Schisantherin B (15 mg/kg; 静脉注射; 每日 3 次) 可改善运动功能、减轻组织损伤、抑制细胞凋亡与炎症反应,并激活 PI3K/AKT 通路以缓解继发性损伤,在小鼠脊髓损伤模型中促进恢复。
Schisantherin B (0.015-0.15 mg/kg; 侧脑室注射;每日 1 次,连续 5 天) 可通过恢复 GLT-1 和 GSK3β 的功能、减少 tau 蛋白过度磷酸化,呈剂量依赖性改善 Aβ1-42 诱导的小鼠认知功能下降与神经元损伤。
Schisantherin B (0.15 mg/kg; 侧脑室注射,每日 1 次,连续 5 天) 可增强健康小鼠的空间学习能力,且不会改变其基础运动活性,也不会引发神经元或生化异常。

Animal Model: KM mice (male, 10-week old, 20-25 g, forced swimming test-induced depression)
Dosage: 15 mg/kg
Administration: i.p.; daily; 10 days
Result: Significantly reduced immobility time and climbing time, and significantly increased swimming time relative to the control group.
Significantly increased spontaneous alternation behavior relative to the control group on day 19; by day 20, spontaneous alternation behavior was comparable to the normal (non-FST) group; by day 27, no differences in alternation behavior were observed between groups.
Significantly increased total distance traveled relative to the control group on day 20.
Significantly restored hippocampal levels of GLT-1, P-PI3K/PI3K, P-AKT/AKT, and P-mTOR/mTOR relative to the control group on day 19.
Animal Model: C57BL/6J Nifdc (8-10-week-old; spinal cord injury model via 12.5 g weight-drop procedure under ketamine/xylazine anesthesia)
Dosage: 15 mg/kg
Administration: i.v.; three times daily
Result: Increased Basso Mouse Scale scores significantly at 21 and 28 days post-injury compared to untreated mice.
Increased hindlimb stride length to ~36 mm and reduced stride width to ~21 mm compared to untreated mice.
Reduced spinal cord cavity size, preserved spinal cord tissue integrity, and increased the number of surviving ventral horn motor neurons.
Reduced the percentage of apoptotic cells and suppressed microglial activation.
Decreased concentrations of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α, and increased concentrations of anti-inflammatory cytokine IL-10.
Increased the proportion of p-PI3K-positive neurons to ~0.5, p-AKT-positive neurons to ~0.45, and upregulated p-PI3K/PI3K and p-AKT/AKT protein expression ratios compared to untreated mice.
Animal Model: KM mice (male, 10-week-old, 25-30 g, intracerebroventricular injection of aggregated Aβ1-42 peptide)
Dosage: 0.015 mg/kg; 0.15 mg/kg
Administration: i.c.v.; daily; 5 days
Result: Showed no significant effect on locomotor activity.
Significantly relieved Aβ1-42-induced reduction in spontaneous alternation behavior in the Y-maze test, with 0.15 mg/kg showing greater efficacy than 0.015 mg/kg.
Significantly ameliorated Aβ1-42-induced increases in escape latency and escape distance in the Morris water maze place navigation test on days 4 and 5 at 0.15 mg/kg.
Restored hippocampal GLT-1 levels to 58.18 pg/mL, cerebral cortex GLT-1 levels to 98.05 pg/mL, reduced hippocampal GSK3β levels to 80.56 pmol/l, cerebral cortex GSK3β levels to 181.22 pmol/l, and restored hippocampal p-GSK3β levels to 217.24 ng/l, cerebral cortex p-GSK3β levels to 215.83 ng/l at 0.15 mg/kg.
Reduced hippocampal p-tau levels to 192.32 ng/l and cerebral cortex p-tau levels to 179.43 ng/l at 0.15 mg/kg.
Normalized hippocampal and cerebral cortex Aβ1-42 levels at 0.15 mg/kg.
Restored hippocampal GLT-1/β-actin, GSK3β/β-actin, p-GSK3β/β-actin, and p-tau/β-actin ratios to near-normal levels at 0.15 mg/kg.
Inhibited Aβ1-42-induced hippocampal neuronal damage (shrunken nuclei, swollen neuronal bodies) as observed via H.E. and Nissl staining at 0.15 mg/kg.
Reduced escape latency in the Morris water maze place navigation test in healthy mice treated with 0.15 mg/kg compared to normal untreated mice.
Maintained near-normal hippocampal and cerebral cortex GLT-1, GSK3β, p-GSK3β, Aβ1-42, and p-tau levels in healthy mice treated with 0.15 mg/kg.
Showed intact, ordered hippocampal neurons in healthy mice treated with 0.15 mg/kg.
Animal Model: KM mice (male, 10-week-old, 25-30 g)
Dosage: 0.15 mg/kg
Administration: i.c.v.; daily; 5 days
Result: Showed no significant effect on locomotor activity or Y-maze spontaneous alternation behavior.
Reduced escape latency in the Morris water maze place navigation test compared to normal untreated mice.
Spent more time in the target quadrant during the Morris water maze spatial probe test.
Maintained near-normal hippocampal and cerebral cortex GLT-1, GSK3β, p-GSK3β, Aβ1-42, and p-tau levels.
Showed intact, ordered hippocampal neurons.
性状 固体
颜色 White to off-white

化学信息

分子量 514.56
分子式 C28H34O9
CAS No. 58546-55-7
别名 五味子酯乙; Gomisin-B; Wuweizi ester-B; Schisantherin-B

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.89 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (97.17 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.9434 mL9.7170 mL19.4341 mL48.5852 mL
5 mM0.3887 mL1.9434 mL3.8868 mL9.7170 mL
10 mM0.1943 mL0.9717 mL1.9434 mL4.8585 mL
15 mM0.1296 mL0.6478 mL1.2956 mL3.2390 mL
20 mM0.0972 mL0.4859 mL0.9717 mL2.4293 mL
25 mM0.0777 mL0.3887 mL0.7774 mL1.9434 mL
30 mM0.0648 mL0.3239 mL0.6478 mL1.6195 mL
40 mM0.0486 mL0.2429 mL0.4859 mL1.2146 mL
50 mM0.0389 mL0.1943 mL0.3887 mL0.9717 mL
60 mM0.0324 mL0.1620 mL0.3239 mL0.8098 mL
80 mM0.0243 mL0.1215 mL0.2429 mL0.6073 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础